Emerging evidence
More
Pharma pharmacists may shift from doing tasks to checking AI work, a commentary argues
Study title: Artificial Intelligence Across the Pharmaceutical Life Cycle: Implications for Industry-Based Clinical Pharmacists
- Evidence type
- Commentary, opinion, or narrative review
- Sources
- 1 sourcePeer-reviewed
- Published
- 1 min read
- Truvace record
- TRV-2026-1246cite or check it
Study title: Artificial Intelligence Across the Pharmaceutical Life Cycle: Implications for Industry-Based Clinical Pharmacists
Published October 1, 2026, this ACCP commentary surveys how artificial intelligence is being applied across the pharmaceutical life cycle and what that means for industry-based clinical pharmacists in development, regulatory, medical affairs, HEOR, and pharmacovigilance.
Read the study abstract
Artificial intelligence (AI) is increasingly shaping the pharmaceutical industry. This ACCP commentary examines the implications of AI for industry-based clinical pharmacists across the pharmaceutical life cycle, including drug development, regulatory affairs, medical affairs, health economics and outcomes research, and pharmacovigilance. Artificial intelligence-enabled tools may support target identification, clinical trial design, regulatory intelligence, evidence synthesis, medical content generation, real-wo…
The gain
AI-enabled tools may support pharmaceutical functions including target identification, trial design, regulatory intelligence, evidence synthesis, and safety signal detection, expanding reach and efficiency.
The problem
AI implementation in pharmaceutical industry functions introduces important risks and practical implementation challenges requiring human oversight.
In brief
It matters because it frames a workforce transition where efficiency gains from AI depend on pharmacists acting as human-in-the-loop validators of scientific validity and clinical relevance, but the piece does not present measured adoption outcomes or performance data, leaving the scale and timing of the shift uncertain.
Main points
- Commentary examines AI implications for industry-based clinical pharmacists across drug development, regulatory affairs, medical affairs, HEOR, and pharmacovigilance.
- AI-enabled tools listed as supporting target identification, clinical trial design, regulatory intelligence, evidence synthesis, medical content generation, RWE analysis, economic modeling, adverse event processing, and safety signal detection.
- Author projects role shift from task execution toward clinical interpretation, quality assurance, strategic decision-making, and governance of AI-supported outputs.
The full story
The commentary maps AI use cases to each stage of the pharmaceutical life cycle, from target identification and trial design to regulatory intelligence, medical content generation, real-world evidence analysis, economic modeling, and adverse event processing.
It argues that as tools mature, pharmacists will need to focus less on manual execution and more on interpreting AI outputs, assuring quality, making strategic decisions, and governing responsible implementation.
Sources
1 on file- JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACYdoi:10.1002/jac5.70300
ace
What readers say